Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Could be but the blastoff began around opening bell. This PR has a time stamp of 10:50 am. Could a sneak peek by someone cause that much buying?
So which would you prefer, a tingle in the toe or death by Covid?
I lost a good friend hospitalized & vented with Covid this past week. In desperation I gave his wife the names and phone numbers of CytoDyn’s top officials tp pass along to my friends physicians. I don’t think they even tried to obtain LL.
They had him on remdesivir and ivermectin.
What happened to the absolutely great newspredicted for this past week?
Typical MO that crooked MM’s use-taking out stop losses that naive stockholders set. Or is it smart MM’s who do this?
Well if I had made those sells I would consider myself a stock scammer with a guilty conscience but stock scammers have no conscience.
Riddle me this-sometime last week NDT was stagnated around $5 and a few hundred share /day. Just for fun, I put in a $3.25 GTC limit bid for 50 shares and forgot about it on my small TDA account. Just a couple of hours ago I was on my Fidelity account (no NDT shares there) and checked NDT SP. To my great surprise, I saw it hit a low of 1.29 this morning & I thought "$h$t, I just lost $2 a share".
Just checked in on my TDA account and to my great surprise my 3.25 bid filled at 1.29 lol,lo.??? I've been playing OTC stocks for over 30 years and have filled at a few cents below bid before but never seen anything like this.
As ecomike has said before funny games being played here.
.34 is the brick wall?? I thought .08 was the brick wall.
And this hitting $8 from a company that has never completed even one IND needed for a tox study the past 15 years! Compare that to IPIX drug studies and one can immediately see how ridiculous it is for us to be hovering around .30 cents.
I didn’t miss anything. I was waiting on predicted GREAT NEWS which apparently didn’t arrive.
Probably won’t hit that .08 brick wall. Thoughts?
Well, I took the initiative to read the date of that conversation and it clearly showed as THURSDAY 1-14-21.
Did I miss the great news from last week?
God bless walnuts and A2-73 for glaucoma, cataracts, and dry eyes.
Ok, thanks for your reply.
Can someone point me to the big news that was expected for this week? TIA.
I refuse to read all caps posts so how is this person correct stating that the RLF board is suppressing SP?
I’m not very good at math so please explain how a 350% gain in one year is bad?
Because that’s just what criminal scammers do to many good stocks IMO.
Was that the day the ‘confusing’ PR came out? If so, it was the neophyte ‘traders’ , not investors, who don’t know a biotech from a banana who sold off.
Excellent questions CTMedic attempting to clarify massive misinformation.
So, it has changed from "a brick wall at .08" to " a brick wall at .23" , from "Flintstone vitamins" to now "Centrum vitamins", lol.
125 million volume and it moved 0%, lol??
Sorc92, looks as if you have good comprehension skills and ‘connect the dots’ intelligence. Yes, my reason for posting that and bolding the paragraph was to show that companies association with UGA, just as SBFM’s association with UGA.
C#M is a well respected biotech who have a head & neck cancer drug awaiting Phase 3 final results. If positive, they will have the only drug in that category which will be medically significant. Some apparently missed this connection with UGA.
So the University of Georgia is not involved in Sunshines trials huh? Ok,lol.
Wow CTMedic, did those late forms cause investors to panic and predict the FBI would knock on Cytodyns office door 5-6 months ago?
Pay attention to the bolded paragraph in this quarterly report and how it relates to Sunshine (SBFM):
CEL-SCI Corporation Reports First Quarter Fiscal 2021 Financial Results
February 16, 2021
CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended December 31, 2020, as well as key clinical and corporate developments.
Clinical and Corporate Developments include:
In December 2020, CEL-SCI updated the status of its pivotal Phase 3 head and neck cancer study of Multikine* (Leukocyte Interleukin, Injection). Data lock has been completed, and the study entered its final stage of statistical analysis. CEL-SCI remains blinded to the study data and is not involved in this process which is conducted by independent contractors. The statistical analysis plan follows the protocol stated objectives and is designed to meet FDA requirements to define the clinical benefits that Multikine might provide for patients newly diagnosed with advanced primary (not yet treated) squamous cell carcinoma of the head and neck. The analysis looks at multiple parameters to gain the most information on the possible benefits of using Multikine immunotherapy as a first line treatment before standard of care for these patients.
CEL-SCI continued expanding and upgrading its dedicated cGMP facility in which it manufactures Multikine. The construction, which began in 2020, is expected to be completed in the coming months and will double the facility’s capacity to accommodate two shifts for increased production of Multikine.
In December 2020, CEL-SCI announced that its LEAPS COV-19 peptides, delivered as a therapeutic treatment following SARS-CoV-2 virus challenge, achieved a 40% survival rate in human ACE2 transgenic mouse model as compared to 0% survival in the two control groups. These studies were conducted at the University of Georgia Center for Vaccines and Immunology. As COVID-19 mutations increase, LEAPS COV-19’s mechanism of action which targets the non-mutating part of the SARS-CoV-2 virus is becoming more important.
In December 2020, CEL-SCI sold 1,000,000 shares of common stock at a public offering price of $14.65 per share and received aggregate proceeds of approximately $13.6 million. On December 31, 2020, CEL-SCI’s cash position was approximately $21.9 million. After December 31, 2020, CEL-SCI has received approximately $3.9 million through the exercise of warrants and stock options.
“As the data analysis for our Phase 3 trial is being conducted, we are focused on expanding manufacturing of Multikine so that we will be ready to produce significant commercial quantities for this unmet medical need. We believe that Multikine may add substantial clinical benefit and help these patients.” stated CEL-SCI CEO, Geert Kersten.
CEL-SCI reported a net loss of approximately $7.9 million for the quarter ended December 31, 2020 versus net loss of approximately $5.5 million for the quarter ended December 31, 2019.
During the three months ended December 31, 2020, CEL-SCI incurred approximately $3.6 million in costs to upgrade its manufacturing facility to prepare for the potential commercial production of Multikine. Total estimated costs of this upgrade are approximately $10.5 million, of which approximately $6.7 million has been incurred through December 31, 2020.
It's up double plus the last month. Is the 10 cent rule still in effect?
Great post. It would be a pleasurable moment to see criminal manipulators incarcerated and posting via a prison library computer.
Ok, thanks.
Tocilizumab results? I was busy yesterday and didn’t follow the boards much but noticed the drug mentioned a few times. I assume they released trial results which weren’t that outstanding. Correct?
Lol.
Rockleo, ‘vaccine roulette’ huh? A friend was in bed for two days after first injection with sickness and pain in arm. Good thing he is retired—-he is a surgeon .
Thanks C24, you’re the only response. I’ve googled the question and only found one item which says “arm choice is left up to recipient”, lol. A friends daughter is a PhD in pandemic diseases and said she had never seen an answer to the question.
Question for any of you covid vaccine experts here; I received my first Moderna jab without any side effects other than a slight soreness when touched. Friday I will receive my second. I'm thinking of using the opposite arm. Why? My uneducated guess is the 'unused' arm will be more 'receptive' because it harbors no 'cytokines' etc, from the first jab. Does that even sound logical? Thanks.
This post should be read and memorized by all the weak hands who panicked and sold or who are still panicky.
Posted byu/afirebrand
22 hours ago
Helpful (Pro)
Gold
Helpful
Hugz
Take My Energy
Relief Therapeutics (RLFTF) & BRPA/NeuroRx Phase 2b/3 Results show 50% reduction in ICU length of stay. So why did the stock tank?
Discussion
First, let me say that I am an intensivist and an investor. I have treated a lot of ICU patients with COVID since this pandemic began. Full disclosure, I own RLF and BRPA and firmly believe VIP/Zyesami works.
Today, phase 2/3b IV trial results were released. It is clear that the market failed to understand the gravity of these results. A market sell off occurred because people thought the trial was a failure because survival at 28days was not statistically significant and because the results failed to address the primary end point of resolution of acute respiratory failure.
You see, the patients who are admitted to the ICU with severe respiratory failure, requiring NIPPV, HFNC or mechanical ventilation are often in concomitant multisystem organ failure with multiple comorbidities of advanced age, poorly controlled diabetes, ESRD, heart failure and obesity.
These patients are critically ill and admitted with acute respiratory failure. They are kept on high flow O2 and NIPPV (BIPAP/CPAP) for as long as possible to decrease ventilator associated barotrauma which has been demonstrated to worsen overall survival in COVID induced RDS.
When patients land on the vent, they are worse now than they ever were a year ago when the pandemic first began. This is because, in the beginning, we were afraid NIPPV would aerosolize COVID and cause a larger spread of the disease. As such, now, patients are kept on HFNC and NIPPV longer than ever. That’s why ICUs are full and remain full. These patients have a tenuous respiratory status and can decompensate at a moment’s notice.
The average length of stay for an ICU COVID admission is 25 days. Decreasing ICU length of stay for HFNC and NIPPV patients by half is huge. I cannot say this enough. The average ICU stay costs $5000 a day. Improvement of ICU hospitalization by 15 days vs. 26 days is an average payor (private insurance/Medicare) cost of 75k vs 130k. That’s a savings of 55k per COVID patient.
(https://www.neurorxpharma.com/press-releases/neurorx-and-relief-therapeutics-report-initial-phase-2b-3-study-results-demonstrating-significant-benefit-of-zyesami-in-reducing-hospital-stay-among-patients-with-respiratory-failure-due-to-c/)
The fact that Zyesami is safe, furthermore, cannot be overlooked. Let us compare these results to the current standard of care. In the NEJM article, Remdesivir for the Treatment of Covid-19 — Final Report, the median time to recovery was shorted by only 1 day with overall disease course shortened from 11 days to 10 days. Remdesivir had a number of side effects, including kidney and liver damage with constant for need for monitoring of LFTs/serum creatinine. (https://www.nejm.org/doi/full/10.1056/NEJMoa2007764)
Furthermore, in regards to steroids, current NIH treatment guidelines note that methylprednisolone did not improve all cause mortality, ICU free days or duration of mechanical ventilation. It only improved the number of ICU days alive and free from mechanical ventilation by a difference of 2.3 days.
(https://www.covid19treatmentguidelines.nih.gov/immune-based-therapy/immunomodulators/corticosteroids/)
The trial results today prove that Zyesami is most useful in mild to moderate COVID before permanent lung damage and multisystem organ failure develop. The best recovery was demonstrated by those patients using HFNC. This strongly suggests that Zyesami prevents disease worsening and reverses mild/moderate disease. An inhaled trial is underway for exactly this indication. Given the degree of improvement seen in LOS, it seems likely an EUA will be granted.
You can ask any physician, myself included, what a big deal cutting ICU stay length in half is. They will all tell you that this is a huge improvement in current standard of care. ICU admission increase risk for nosocomial infections, worsening respiratory status and debility. Furthermore, given its positive effect in patients on NIPPV/HFNC, current evidence supports that VIP may have a significant benefit in other respiratory diseases, like COPD, asthma and interstitial pneumonitis.
As such, I think that the market has misunderstood the results to date. Today’s market activity was an over-reaction (just like when this tanked to 29c in Dec). This price activity has already began to correct from a low of 31c to 41c today. I expect prices to begin to recover and people start to understand the gravity of these results in the near future when a full data is released, with comparison xrays, ordinal scales and 28/60 day outcomes. Biotech are volatile by nature, but I am also strongly optimistic for an EUA.
4
1
1
114
Comments
Give Award
Share
Save
Hide
Report
98% Upvoted
Brilacidin (IPIX) for Covid-19 testing makes the Virus Journal:
https://www.mdpi.com/1999-4915/13/2/271
Brilacicin for Covid-19 testing made the Virus Journal:
https://www.mdpi.com/1999-4915/13/2/271
BPTH up over 300% on new cancer patent news.
Thanks. Must be the best patent they have ever had